UBS Group Forecasts Strong Price Appreciation for Pfizer (NYSE:PFE) Stock

Pfizer (NYSE:PFE) had its price objective boosted by stock analysts at UBS Group from $24.00 to $25.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s price objective would indicate a potential upside of 4.57% from the company’s previous close.

PFE has been the subject of a number of other reports. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $29.64.

Pfizer Trading Down 2.1 %

NYSE PFE opened at $23.91 on Wednesday. Pfizer has a 52 week low of $20.92 and a 52 week high of $31.54. The firm has a 50 day moving average of $24.39 and a two-hundred day moving average of $25.82. The stock has a market capitalization of $135.59 billion, a PE ratio of 16.96, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.82 earnings per share. As a group, research analysts expect that Pfizer will post 2.95 EPS for the current fiscal year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.06% of the stock is owned by insiders.

Institutional Trading of Pfizer

Institutional investors have recently modified their holdings of the business. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer during the 4th quarter worth $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $27,000. Gould Capital LLC increased its stake in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer during the fourth quarter worth $28,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.